Lee Hae Young, Ko Seung-Hyun, Park Sungjoon, Kim Kyuho, Kim Song-Yi, Cho In-Jeong, Cho Eun Joo, Kim Hyeon Chang, Park Jae-Hyeong, Ryu Sung Kee, Moon Min Kyong, Ihm Sang-Hyun
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Department of Internal Medicine, Division of Endocrinology and Metabolism, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Clin Hypertens. 2024 Sep 1;30(1):24. doi: 10.1186/s40885-024-00279-4.
Obesity is the one of the most important components of metabolic syndrome. Because obesity related hypertension accounts for two thirds of essential hypertension, managing obesity and metabolic syndrome is a crucial task in the management of hypertension. However, the current non-pharmacological therapies have limitations for achieving or maintaining ideal body weight. Recently, glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstrated excellent weight control effects, accompanied by corresponding reductions in blood pressure. GLP1-RAs have shown cardiovascular and renal protective effects in cardiovascular outcome trials both in primary and secondary prevention. In this document, the Korean Society of Hypertension intends to remark the current clinical results of GLP1-RAs and recommend the government and health-policy makers to define obesity as a disease and to establish forward-looking policies for GLP1-RA treatment for obesity treatment, including active reimbursement policies.
肥胖是代谢综合征最重要的组成部分之一。由于与肥胖相关的高血压占原发性高血压的三分之二，因此管理肥胖和代谢综合征是高血压管理中的一项关键任务。然而，当前的非药物疗法在实现或维持理想体重方面存在局限性。最近，胰高血糖素样肽-1受体激动剂（GLP1-RAs）已显示出出色的体重控制效果，同时伴有血压相应降低。在心血管结局试验中，GLP1-RAs在一级和二级预防中均显示出心血管和肾脏保护作用。在本文件中，韩国高血压学会打算阐述GLP1-RAs的当前临床结果，并建议政府和卫生政策制定者将肥胖定义为一种疾病，并制定前瞻性政策，以促进GLP1-RA用于肥胖治疗，包括积极的报销政策。
